k-ras mutation status analysis Search Results


idh1/2 mutation detection kit  (EntroGen Inc)
90
EntroGen Inc idh1/2 mutation detection kit
Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C <t>IDH1</t> R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing
Idh1/2 Mutation Detection Kit, supplied by EntroGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+braf+mutation+analysis+kit/pmc09626418-126-22-28
Average 90 stars, based on 1 article reviews
idh1/2 mutation detection kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
kras mutation analysis kit  (EntroGen Inc)
90
EntroGen Inc kras mutation analysis kit
Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C <t>IDH1</t> R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing
Kras Mutation Analysis Kit, supplied by EntroGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+mutation+analysis+kit/pm26970585-188-15-14
Average 90 stars, based on 1 article reviews
kras mutation analysis kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
colon adenocarcinoma specimens known kras braf mutation status  (BioIVT Inc)
90
BioIVT Inc colon adenocarcinoma specimens known kras braf mutation status
Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C <t>IDH1</t> R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing
Colon Adenocarcinoma Specimens Known Kras Braf Mutation Status, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/colon+adenocarcinoma+specimens+known+kras+braf+mutation+status/pmc06386588-968-9-15
Average 90 stars, based on 1 article reviews
colon adenocarcinoma specimens known kras braf mutation status - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
k-ras mutation analysis kit  (EntroGen Inc)
90
EntroGen Inc k-ras mutation analysis kit
Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C <t>IDH1</t> R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing
K Ras Mutation Analysis Kit, supplied by EntroGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/k+ras+mutation+analysis+kit/pm27681866-160-1-0
Average 90 stars, based on 1 article reviews
k-ras mutation analysis kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
analysis of kras mutations  (BML Inc)
90
BML Inc analysis of kras mutations
Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C <t>IDH1</t> R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing
Analysis Of Kras Mutations, supplied by BML Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/analysis+of+kras+mutations/pmc07487580-78-3-15
Average 90 stars, based on 1 article reviews
analysis of kras mutations - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
kras mutation analysis  (OSI Pharmaceuticals)
90
OSI Pharmaceuticals kras mutation analysis
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
Kras Mutation Analysis, supplied by OSI Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+mutation+analysis/pmc03179254-249-17-21
Average 90 stars, based on 1 article reviews
kras mutation analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
kras mutation analysis kit for realtime pcr (exons 2, 3, and 4)  (EntroGen Inc)
90
EntroGen Inc kras mutation analysis kit for realtime pcr (exons 2, 3, and 4)
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
Kras Mutation Analysis Kit For Realtime Pcr (Exons 2, 3, And 4), supplied by EntroGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+mutation+analysis+kit+for+realtime+pcr++exons+2++3++and+4+/pm36428704-97-11-18
Average 90 stars, based on 1 article reviews
kras mutation analysis kit for realtime pcr (exons 2, 3, and 4) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
kras mutational analysis  (Nagai Nori USA INC)
90
Nagai Nori USA INC kras mutational analysis
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
Kras Mutational Analysis, supplied by Nagai Nori USA INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+mutational+analysis/pm28291966-115-28-16
Average 90 stars, based on 1 article reviews
kras mutational analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
16 (kras mutation analysis)  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare 16 (kras mutation analysis)
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
16 (Kras Mutation Analysis), supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/16++kras+mutation+analysis+/10__1158_slash_0008___5472__can___10___1204-59-1-8
Average 90 stars, based on 1 article reviews
16 (kras mutation analysis) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
diagnostic pcr-based analysis of kras mutations  (Devyser AB)
90
Devyser AB diagnostic pcr-based analysis of kras mutations
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
Diagnostic Pcr Based Analysis Of Kras Mutations, supplied by Devyser AB, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/diagnostic+pcr+based+analysis+of+kras+mutations/pm29301749-245-11-3
Average 90 stars, based on 1 article reviews
diagnostic pcr-based analysis of kras mutations - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
k-ras mutation status analysis  (Response Genetics Inc)
90
Response Genetics Inc k-ras mutation status analysis
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
K Ras Mutation Status Analysis, supplied by Response Genetics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/k+ras+mutation+status+analysis/pm21931273-185-4-22
Average 90 stars, based on 1 article reviews
k-ras mutation status analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
kras mutation analysis  (LabCorp)
90
LabCorp kras mutation analysis
Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics
Kras Mutation Analysis, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-ras+mutation+status+analysis/kras+mutation+analysis/pm24956168-90-0-7
Average 90 stars, based on 1 article reviews
kras mutation analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C IDH1 R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing

Journal: Molecular Diagnosis & Therapy

Article Title: Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics

doi: 10.1007/s40291-022-00612-3

Figure Lengend Snippet: Examples of the most common pathogenic variants detected by NGS. The black arrows show the position of the detected variant. Abnormalities were assessed using TIER 2017 Variant Classification and AMCG 2015. A TERT promoter upstream gene variant NC_000005.9: g.1295228G>A TIER I; pathogenic. B TERT promoter upstream gene variant NC_000005.9:g.1295250G>A TIER I; pathogenic. C IDH1 R132H missense variant NM_005896.2:c.395G>A (p.Arg132His) TIER I. D IDH1 R132S missense variant NM_005896.2:c.394C>A (p.Arg132Ser) TIER II; Likely pathogenic. E PIK3CA missense variant NM_006218.2:c.1633G>A (p.Glu545Lys) TIER I; pathogenic. F BRAF missense variant NM_004333.4:c.1799T>A (p.Val600Glu) TIER I; pathogenic. NGS next-generation sequencing

Article Snippet: The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively.

Techniques: Variant Assay, Next-Generation Sequencing

Evaluation of IDH1 status obtained by non-reference center (IHC), with 3 molecular methods (NGS, qPCR, Sanger) obtained by reference oncology center

Journal: Molecular Diagnosis & Therapy

Article Title: Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics

doi: 10.1007/s40291-022-00612-3

Figure Lengend Snippet: Evaluation of IDH1 status obtained by non-reference center (IHC), with 3 molecular methods (NGS, qPCR, Sanger) obtained by reference oncology center

Article Snippet: The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively.

Techniques: Mutagenesis

Evaluation of IDH1 status received from non-reference center (MLPA), with 3 molecular methods (NGS, qPCR, Sanger) received from reference oncology center

Journal: Molecular Diagnosis & Therapy

Article Title: Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics

doi: 10.1007/s40291-022-00612-3

Figure Lengend Snippet: Evaluation of IDH1 status received from non-reference center (MLPA), with 3 molecular methods (NGS, qPCR, Sanger) received from reference oncology center

Article Snippet: The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively.

Techniques: Mutagenesis

Examples of IHC and MLPA reports from different non-oncological reference centers versus NGS, qPCR, and Sanger sequencing results from the oncology reference center. Two false positives were detected by MLPA and IHC, and one false negative by IHC. Pathogenic variants detected by NGS were additionally validated by two independent methods: Sanger sequencing and qPCR. The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively. Two red curves represent (1) positive control and (2) amplicon with mutation detected ( arrow ). The patient no. 13 – MLPA report indicates IDH-wildtype, while NGS, qPCR, and Sanger sequencing confirmed mutation in the IDH1 gene. IHC immunohistochemistry, MLPA multiplex ligation-dependent probe amplification, NGS next-generation sequencing, qPCR quantitative polymerase chain reaction

Journal: Molecular Diagnosis & Therapy

Article Title: Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics

doi: 10.1007/s40291-022-00612-3

Figure Lengend Snippet: Examples of IHC and MLPA reports from different non-oncological reference centers versus NGS, qPCR, and Sanger sequencing results from the oncology reference center. Two false positives were detected by MLPA and IHC, and one false negative by IHC. Pathogenic variants detected by NGS were additionally validated by two independent methods: Sanger sequencing and qPCR. The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively. Two red curves represent (1) positive control and (2) amplicon with mutation detected ( arrow ). The patient no. 13 – MLPA report indicates IDH-wildtype, while NGS, qPCR, and Sanger sequencing confirmed mutation in the IDH1 gene. IHC immunohistochemistry, MLPA multiplex ligation-dependent probe amplification, NGS next-generation sequencing, qPCR quantitative polymerase chain reaction

Article Snippet: The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively.

Techniques: Sequencing, Next-Generation Sequencing, Mutagenesis, Positive Control, Amplification, Immunohistochemistry, Multiplex Assay, Ligation, Real-time Polymerase Chain Reaction

Journal: Molecular Diagnosis & Therapy

Article Title: Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics

doi: 10.1007/s40291-022-00612-3

Figure Lengend Snippet:

Article Snippet: The black arrows indicate mutations detected using next-generation sequencing (NGS Targeted Hotspot Panel, Entrogen), Sanger sequencing (Applied Biosystems SeqStudio Genetic Analyzer), and qPCR ( IDH1/2 Mutation Detection Kit, Entrogen), with a limit of detection of 5, 20, and 1%, respectively.

Techniques: Next-Generation Sequencing, Real-time Polymerase Chain Reaction

Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics

Journal: Journal of Clinical Oncology

Article Title: A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer

doi: 10.1200/JCO.2010.34.4929

Figure Lengend Snippet: Biomarker Results On the Basis of Treatment Arm and Key Patient Characteristics

Article Snippet: With consent, the remnant tissue was used for EGFR mutation testing by Genzyme Genetics (Westborough, MA) and KRAS mutation analysis by OSI Pharmaceuticals (Boulder, CO).

Techniques: Biomarker Assay, Mutagenesis

Thirty-six patients were fluorescent in situ hybridization negative, KRAS wild type (WT), and EGFR WT.

Journal: Journal of Clinical Oncology

Article Title: A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer

doi: 10.1200/JCO.2010.34.4929

Figure Lengend Snippet: Thirty-six patients were fluorescent in situ hybridization negative, KRAS wild type (WT), and EGFR WT.

Article Snippet: With consent, the remnant tissue was used for EGFR mutation testing by Genzyme Genetics (Westborough, MA) and KRAS mutation analysis by OSI Pharmaceuticals (Boulder, CO).

Techniques: In Situ Hybridization

Analyses of PFS and OS for Biomarker Subsets

Journal: Journal of Clinical Oncology

Article Title: A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer

doi: 10.1200/JCO.2010.34.4929

Figure Lengend Snippet: Analyses of PFS and OS for Biomarker Subsets

Article Snippet: With consent, the remnant tissue was used for EGFR mutation testing by Genzyme Genetics (Westborough, MA) and KRAS mutation analysis by OSI Pharmaceuticals (Boulder, CO).

Techniques: Biomarker Assay, Mutagenesis

Response by Biomarker Status

Journal: Journal of Clinical Oncology

Article Title: A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer

doi: 10.1200/JCO.2010.34.4929

Figure Lengend Snippet: Response by Biomarker Status

Article Snippet: With consent, the remnant tissue was used for EGFR mutation testing by Genzyme Genetics (Westborough, MA) and KRAS mutation analysis by OSI Pharmaceuticals (Boulder, CO).

Techniques: Biomarker Assay, Mutagenesis